Compensation in the brain could lead to new treatment

November 13, 2012

New evidence indicates that Parkinson's disease is preceded by a period during which healthy regions of the brain take over the functions of damaged ones. Neurologist Bart van Nuenen performed a unique study involving people who are clinically still healthy and free from disease manifestations, but who have an increased risk of developing Parkinson's disease later in life due to their genetic predisposition. Van Nuenen will defend his PhD thesis based on this study on 22 November.

Parkinson's disease results from the death of that produce dopamine. Remarkably, the physical symptoms of Parkinson's disease (tremor, rigidity and slowness of movement) do not appear until 50% to 70% of the dopamine-producing cells have died. It has long been a mystery why the physical symptoms take so long to develop.

In recent years, multiple have been discovered that cause Parkinson's symptoms. In collaboration with various international research groups, the research group of Prof. Bas Bloem at the Radboud University Nijmegen Medical Centre conducted a study of families in Germany, Italy and Israel that have such a mutation in a Parkinson's gene. Parkinson's disease is very common in these families, but some family members do not yet show symptoms of the disease despite having the mutation. This allowed for an effective study of the preclinical phase of the disease, i.e. the period that precedes the manifestation of physical motor symptoms. The study was conducted with the aid of advanced for functional (fMRI scanners).

Healthy brain region

One of the investigators in the study, Bart van Nuenen - who currently works as a at the Catharina Hospital in Eindhoven - asked the to perform various tasks. At the same time, he conducted fMRI scans of their brain. He did the same with a control group of individuals who do not have Parkinson's disease in their family. Both groups were entirely healthy in clinical terms, and both groups performed the tasks equally well. However, the analysis of the MRI scans showed that the brain activity of the genetically predisposed group differed from that of the control group. In particular, the genetically predisposed group showed enhanced activity in a specific area of the brain -the extrastriate body area - that also remains unaffected in the late stages of Parkinson's disease. Apparently, in the genetically predisposed group this healthy brain area compensates for the declining function of brain areas that are already being affected by the disease. Due to this compensation, the test subjects could still move normally and suppress the Parkinson's symptoms.


To conclusively demonstrate that this overactive brain area actually contributes to compensation, Van Nuenen conducted an additional experiment using transcranial magnetic stimulation (TMS). This technique can temporarily deactivate a specific area of the brain. When Van Nuenen deactivated the extrastriate body area by using TMS, Parkinson's patients were temporarily unable to perform certain hand motions correctly. In the healthy control group, the deactivation of the extrastriate body area did not have this effect. This makes it very likely that compensation in the brain occurs during the preclinical phase, and that this compensation delays the clinical manifestation of Parkinson's disease.

This finding is crucial for understanding the processes that play a role during the very early stages of Parkinson's disease. Van Nuenen explains: 'Conventional treatments have focused exclusively on correcting the dopamine deficiency. But now we have a starting point for a new type of therapy that focuses on stimulating the compensation mechanism. If this therapy is successful, not only can we suppress symptoms more effectively, but perhaps even postpone the clinical presentation of the disease in carriers of a Parkinson's gene mutation.'

Explore further: Healthy welders may be at increased risk for early brain damage

More information: Bart F.L. van Nuenen. "Cerebral reorganization in premotor parkinsonism." PhD thesis. Date of PhD defence: 22 November 2012. PhD supervisors: Prof. B.R. Bloem, Prof. I. Toni, Prof. H.R. Siebner (University of Copenhagen).

Related Stories

Healthy welders may be at increased risk for early brain damage

April 6, 2011
New research suggests that workers exposed to welding fumes may be at risk for developing brain damage in an area of the brain also affected in Parkinson's disease. The study is published in the April 6, 2011, online issue ...

Simple blood test diagnoses Parkinson's disease long before symptoms appear

November 30, 2011
A new research report appearing in the December issue of the FASEB Journal shows how scientists from the United Kingdom have developed a simple blood test to detect Parkinson's disease even at the earliest stages. The test ...

Recommended for you

Scientists solve 3-D structure of key defense protein against Parkinson's disease

October 5, 2017
Scientists at the University of Dundee have identified the structure of a key enzyme that protects the brain against Parkinson's disease.

Novel protein interactions explain memory deficits in Parkinson's disease

September 26, 2017
A study published in the journal Nature Neuroscience describes the identification of a novel molecular pathway that can constitute a therapeutic target for cognitive defects in Parkinson's disease. The study showed that abnormal ...

Psychosis in Parkinson's dementia—new treatment provides hope

September 25, 2017
New research involving King's College London and the University of Exeter has highlighted the benefits of a promising new treatment which could relieve psychosis in thousands of people with dementia related to Parkinson's ...

Bicycling 'overloads' movement networks with Parkinson's

September 23, 2017
(HealthDay)—Bicycling suppresses abnormal beta synchrony in the Parkinsonian basal ganglia, according to a study published online Sept. 11 in the Annals of Neurology.

Researchers find new path to promising Parkinson's treatment

September 19, 2017
Three researchers at The University of Alabama are part of work that is leading to a new direction for drug discovery in the quest to treat Parkinson's disease.

Tug of war between Parkinson's protein and growth factor

September 18, 2017
Alpha-synuclein, a sticky and sometimes toxic protein involved in Parkinson's disease (PD), blocks signals from an important brain growth factor, Emory researchers have discovered.


Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.